10028251

=> d his

(FILE 'HOME' ENTERED AT 18:23:51 ON 16 JUL 2003)

FILE 'REGISTRY' ENTERED AT 18:24:02 ON 16 JUL 2003
L1 STRUCTURE UPLOADED
L2 0 S L1
L3 5 S L1 SSS FULL

FILE 'CAPLUS' ENTERED AT 18:32:25 ON 16 JUL 2003
L4 2 S L3

FILE 'MARPAT' ENTERED AT 18:33:11 ON 16 JUL 2003
L5 0 S L3
L6 2 S L3 SSS FULL

FILE 'CAPLUS' ENTERED AT 18:33:58 ON 16 JUL 2003
L7 2 S L6

=> s l7 not l4
L8 0 L7 NOT L4

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 C,N
G2 C,S

Structure attributes must be viewed using STN Express query preparation.

10028251

=> d 1-2 bib abs hitstr

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2003 ACS
AN 2002:237357 CAPLUS
DN 136:263174
TI Preparation of 4-[5,6-dihydro-1H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]piperazine-2-carboxylates and analogs as farnesyl protein transferase inhibitors
IN Guzi, Timothy; Rane, Dinanath F.; Mallams, Alan K.; Cooper, Alan B.; Doll, Ronald J.; Girijavallabhan, Viyyoor M.; Taveras, Arthur G.; Strickland, Corey; Kelly, Joseph M.; Chao, Jianping
PA Schering Corporation, USA
SO U.S., 239 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6362188	B1	20020326	US 1999-465523	19991216
	US 2003040520	A1	20030227	US 2001-28251	20011220
PRAI	US 1998-112943P	P	19981218		
	US 1999-465523	A3	19991216		

OS MARPAT 136:263174
GI



AB Title compds. [I; R1R2 = (un)substituted CH:CHCH:CH, N:CHCH:CH, CH:CHCH:N, etc.; R3R4 = (un)substituted CH:CHCH:CH; R5 = H or 1-3 of alkyl, aryl, COR10, etc.; R6 = H; R5R6 = O or S; R7 = COR8; R8 = Z1R12; R9 = (esterified) CO2H, (un)substituted CONH2, alkanoyl, etc.; R10 = H, (ar)alkyl, aryl; R12 = (un)substituted imidazolyl or pyridyl; X = N, CH, C; Z = (un)substituted CH:CH or CH2CH2; Z1 = N-attached heterocyclylene; dashed bond = optional bond] were prepd. Thus, title compd. II (R = H) was amidated by (S)-3-(1-imidazolylmethyl)piperidine (prepn. each given) to give II [R = (S)-3-(1-imidazolylmethyl)piperidin-1-yl]. Data for biol. activity of I were given.
IT **278786-29-1P 278786-30-4P 278786-31-5P**
278786-32-6P 278786-33-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of 4-[5,6-dihydro-1H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]piperazine-2-carboxylates and analogs as farnesyl protein transferase inhibitors)
RN 278786-29-1 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[(11S)-3-bromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-2-[[(3R)-3-(1H-imidazol-1-ylmethyl)-1-piperidinyl]carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 278786-30-4 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[(11S)-3-bromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-2-[[(3R)-3-[(2-methyl-1H-imidazol-1-yl)methyl]-1-piperidinyl]carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 278786-31-5 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[(11R)-3-bromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-2-[[(3R)-3-[(2-methyl-1H-imidazol-1-yl)methyl]-1-piperidinyl]carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 278786-32-6 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[(11R)-3-bromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-2-[[(3S)-3-(1H-imidazol-1-ylmethyl)-1-piperidinyl]carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10028251



RN 278786-33-7 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[(11S)-3-bromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-2-[[(3S)-3-(1H-imidazol-1-ylmethyl)-1-piperidinyl]carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2003 ACS
AN 2000:441785 CAPLUS
DN 133:74034
TI Preparation of 4-[5,6-dihydro-1H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]piperazine-2-carboxylates and analogs as farnesyl protein transferase inhibitors
IN Guzi, Timothy; Rane, Dinanath F.; Mallams, Alan K.; Cooper, Alan B.; Doll, Ronald J.; Girijavallabhan, Viyyoor M.; Taveras, Arthur G.; Strickland, Corey; Kelly, Joseph M.; Chao, Jianping
PA Schering Corporation, USA
SO PCT Int. Appl., 359 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000037458	A1	20000629	WO 1999-US27938	19991216
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, NO, NZ, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	BR 9916328	A	20011002	BR 1999-16328	19991216
	EP 1140904	A1	20011010	EP 1999-967139	19991216
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	JP 2002533335	T2	20021008	JP 2000-589530	19991216
	NO 2001002960	A	20010815	NO 2001-2960	20010615
PRAI	US 1998-216560	A	19981218		

10028251

WO 1999-US27938 W 19991216
OS MARPAT 133:74034
GI



I



II

AB Title compds. [I; R1R2 = (un)substituted CH:CHCH:CH, -N:CHCH:CH, -CH:CHCH:N, etc.; R3R4 = (un)substituted CH:CHCH:CH; R5 = H or 1-3 of alkyl, aryl, COR10, etc.; R6 = H; R5R6 = O or S; R7 = COR8; R8 = Z1R12; R9 = (esterified) CO2H, (un)substituted CONH2, alkanoyl, etc.; R10 = H, (ar)alkyl, aryl; R12 = (un)substituted imidazolyl or pyridyl; X = N, CH, C; Z = (un)substituted CH:CHCH:CH or -CH2CH2; Z1 = N-attached heterocyclylene; dashed bond = optional bond] were prepd. Thus, title compd. II (R = H) was amidated by (S)-3-(1-imidazolylmethyl)piperidine (prepn. each given) to give II [R = (S)-3-(1-imidazolylmethyl)piperidin-1-yl]. Data for biol. activity of I were given.

IT **278786-29-1P 278786-30-4P 278786-31-5P**
278786-32-6P 278786-33-7P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of 4-[5,6-dihydro-1H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]piperazine-2-carboxylates and analogs as farnesyl protein transferase inhibitors)

RN 278786-29-1 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[(11S)-3-bromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-2-[[(3R)-3-(1H-imidazol-1-ylmethyl)-1-piperidinyl]carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 278786-30-4 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[(11S)-3-bromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-2-[[(3R)-3-[(2-methyl-1H-imidazol-1-yl)methyl]-1-piperidinyl]carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 278786-31-5 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[(11R)-3-bromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-2-[[(3R)-3-[(2-methyl-1H-imidazol-1-yl)methyl]-1-piperidinyl]carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 278786-32-6 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[(11R)-3-bromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-2-[[(3S)-3-(1H-imidazol-1-ylmethyl)-1-piperidinyl]carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 278786-33-7 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[(11S)-3-bromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-2-[[(3S)-3-(1H-imidazol-1-ylmethyl)-1-piperidinyl]carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10028251



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT